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Kynurenine metabolic balance is disrupted
in the hippocampus following peripheral
lipopolysaccharide challenge
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Abstract
Background: Inflammation increases the risk of developing depression-related symptoms, and tryptophan metabolism
is an important mediator of these behavior changes. Peripheral immune activation results in central up-regulation of
pro-inflammatory cytokine expression, microglia activation, and the production of neurotoxic kynurenine metabolites.
The neuroinflammatory and kynurenine metabolic response to peripheral immune activation has been largely
characterized at the whole brain level. It is unknown if this metabolic response exhibits regional specificity even
though the unique indoleamine 2,3-dioxygenase (IDO)-dependent depressive-like behaviors are known to be
controlled by discrete brain regions. Therefore, regional characterization of neuroinflammation and kynurenine
metabolism might allow for better understanding of the potential mechanisms that mediate inflammation-associated
behavior changes.
Methods: Following peripheral immune challenge with lipopolysaccharide (LPS), brain tissue from behaviorally
relevant regions was analyzed for changes in mRNA of neuroinflammatory targets and kynurenine pathway
enzymes. The metabolic balance of the kynurenine pathway was also determined in the peripheral circulation
and these brain regions.
Results: Peripheral LPS treatment resulted in region-independent up-regulation of brain expression of pro-inflammatory
cytokines and glial cellular markers indicative of a neuroinflammatory response. The expression of kynurenine pathway
enzymes was also largely region-independent. While the kynurenine/tryptophan ratio was elevated significantly in both
the plasma and in each brain regions evaluated, the balance of kynurenine metabolism was skewed toward production
of neurotoxic metabolites in the hippocampus.
Conclusions: The upstream neuroinflammatory processes, such as pro-inflammatory cytokine production, glial cell
activation, and kynurenine production, may be similar throughout the brain. However, it appears that the balance of
downstream kynurenine metabolism is a tightly regulated brain region-dependent process.
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Background
The behavioral consequences of inflammation and
pro-inflammatory cytokines have been well described,
both clinically and preclinically. Chronic diseases,
often characterized by prolonged immune activation,
are associated with an increased risk of comorbid depres-
sion diagnosis [1]. Approximately 50–80 % of patients
receiving interferon-α (IFN-α) immunotherapy for hepa-
titis C or malignant melanoma develop depression-related
symptoms during the course of treatment, including neu-
rovegetative, affective, and/or cognitive impairment [2].
Administration of endotoxin or vaccines to healthy vol-
unteers induces transient depression-associated symp-
toms that parallel the appearance of pro-inflammatory
cytokines [3–6], whereas direct administration of pro-
inflammatory cytokines in preclinical models recapitu-
lates inflammation-associated depressive-like behaviors
[7–10]. Pharmacological or genetic inhibition of pro-
inflammatory cytokine action effectively attenuates many
of the inflammation-induced depressive-like behaviors in
rodents, establishing that pro-inflammatory cytokines are
necessary to precipitate this behavioral response [11, 12].
Clearly, pro-inflammatory cytokines are important patho-
genic mediators of depression-related behavior changes
resulting from immune stimulation; however, the specific
mechanism by which this occurs is not clearly defined.
Peripheral immune activation and subsequent produc-
tion of pro-inflammatory cytokines communicate im-
mune status to the brain via multiple routes, where the
inflammatory signals are locally propagated by microglia,
the resident immune cells [13]. While the initial neu-
roinflammatory response may be part of an adaptive
beneficial process, excessive or chronic neuroinflamma-
tion has been associated with adverse neurological con-
sequences [14, 15]. These consequences can include the
disruption of neurotransmission, neurotrophin signaling,
hypothalamic-pituitary-adrenal (HPA) axis activation, and
alteration of metabolic pathways [13]. One metabolic
pathway hypothesized to be important in mediating the ef-
fects of pro-inflammatory cytokines in the brain is the
kynurenine pathway of tryptophan metabolism (Fig. 1),
the major route of central tryptophan breakdown [16].
Pro-inflammatory cytokines up-regulate the expression
and activity of indoleamine 2,3-dioxygenase (IDO, Fig. 1),
the rate-limiting enzyme of the kynurenine pathway, in-
creasing flux through the pathway [17–19]. During basal
conditions, kynurenine is further metabolized to kynure-
nic acid (KA, Fig. 1), an N-methyl-D-aspartate receptor
(NMDAR) antagonist and an α7-nicotinic acetylcholine re-
ceptor (α7nAChR) negative allosteric modulator [20, 21].
However, during neuroinflammatory conditions, the
“neurotoxic” branch of kynurenine metabolism is up-regu-
lated, which drives the synthesis of several neuroactive me-
tabolites, including quinolinic acid (QA, Fig. 1), an
NMDAR agonist and neurotoxic metabolite [20, 22, 23].
This shift in kynurenine pathway balance, increasing the
production of neurotoxic QA relative to KA, that occurs
during neuroinflammation, is hypothesized to underlie
inflammation-associated depression-related behaviors [24].
Inhibition or genetic removal of IDO demonstrated the ne-
cessity of kynurenine metabolism to the development of
inflammation-induced depressive-like behaviors in rodents
[19, 25, 26]. Further, antagonism of the NMDAR with keta-
mine attenuated inflammation-induced anhedonia and be-
havioral despair, implicating activation of NMDAR by QA,
as a mechanism that induces inflammation-associated
depressive-like behaviors [23]. Interferon-α immunotherapy
resulted in elevated serum kynurenine/tryptophan ratio,
indicative of increased IDO activity, as well as increased
cerebrospinal fluid (CSF) levels of kynurenine, KA, and QA
[27, 28]. Only CSF QA was significantly positively associ-
ated with Montgomery-Asberg Depression Rating Scale
(MADRS) scores in these patients [28]. However, to date,
inflammation-induced changes in kynurenine metabolism
have largely been measured in whole brain samples even
though distinct, regionally specific neurocircuitry controls
the various symptom dimensions of depression.
Depression symptomatology is heterogeneous through-
out the patient population, complicating research efforts
targeted at understanding the neurobiological substrates
underlying the disease. Because of this, the National
Institute of Mental Health (NIMH) established the
Research Domain Criteria (RDoC, http://www.nimh.
nih.gov/research-priorities/rdoc/index.shtml) as a con-
struct for mental health research [29, 30]. Rather than
defining patient populations by a disease diagnosis, the
RDoC instead prompts investigators to focus on under-
standing the mechanism that underlies specific symp-
toms or behaviors. In healthy volunteers, endotoxin
administration results in anhedonia, disruption in cog-
nitive performance, anxiety, and mood disturbances
[31, 32]. These endotoxin-associated symptoms have
been associated with altered blood flow (imaged using
functional magnetic resonance imaging (fMRI)) in the
ventral striatum, amygdala, and dorsomedial prefrontal
cortex among other regions [5, 33, 34]. Similar to
human patients, lipopolysaccharide (LPS, endotoxin)
challenge in mice results in similar behaviors (anhedo-
nia, anxiety, behavioral despair, cognitive disruption)
[19, 25, 26]. Determining the relevant regional neuroin-
flammatory response, particularly kynurenine metabol-
ism, following peripheral immune activation with LPS
will lead to a better understanding of the development
of these behaviors.
While the region-specific expression of pro-inflammatory
cytokines after peripheral immune challenge has been par-
tially characterized [17, 35], the impact of peripheral LPS
challenge on kynurenine pathway enzyme expression and
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subsequent metabolism has only been described at the
whole brain level [23]. Here, we tested the hypothesis that
up-regulation of kynurenine pathway enzymes and disrup-
tion of kynurenine metabolic balance occurs in a regionally
distinct manner. Brain regions associated with depressive-
like behaviors were collected following peripheral immune
challenge with LPS in mice. The steady-state mRNA
expression of markers of glial activation, pro-inflammatory
cytokines, and kynurenine pathway enzymes were mea-
sured. Tryptophan and its metabolites were also measured
in each brain region. The brain regions assessed included
the hippocampus, the amygdala, and the ventral striatum
(nucleus accumbens). Dysfunction in these brain regions
has been reported in depressed patients and is hypothesized
to be a critical pathogenic mechanism underlying distinct
depression-associated behaviors [36]. Because the periph-
ery is reported to provide much of the brain’s kynurenine
[37], plasma metabolite levels were also measured. The
data demonstrate that peripheral LPS treatment elevates
the expression of pro-inflammatory cytokines and glial cell
markers similarly in each region. IDO expression, but not
IDO2 or tryptophan 2,3-dioxygenase (TDO), was signifi-
cantly up-regulated after LPS treatment. Consistent
with IDO up-regulation, the kynurenine/tryptophan
ratio was elevated in each region; however, the 3-
hydroxykynurenine (3-HK)/KA ratio, an indicator of a
neurotoxic imbalance in kynurenine metabolism, was
only increased in the hippocampus (dorsal and ventral).
These data are the first that characterize the brain
region-specific metabolic response of the kynurenine
pathway following peripheral LPS challenge.
Methods
Animals
All animal care and use was conducted in accord with the
Guide for the Care and Use of Laboratory Animals, eighth
edition (NRC), and protocols were approved by the Institu-
tional Animal Care and Use Committee at the University of
Texas Health Science Center at San Antonio (UTHSCSA).
Male C57BL/6J mice were obtained from Jackson Labora-
tory (Bar Harbor, ME; stock# 000664) and were used at ages
between 8 and 12 weeks of age (adults). Prior to use, mice
were group housed in standard shoebox cages, allowed ad
libitum food and water access, and general health was mon-
itored daily by veterinary technicians or research staff.
Treatment
Lipopolysaccharide (Sigma, St. Louis, MO) isolated from
Escherichia coli (L-3129, serotype 0127:B8) was prepared
fresh on the morning of injections and was dissolved in
sterile, endotoxin-free 0.9 % saline (vehicle) and injected
intraperitoneally (i.p.) at a dose of 0.5 mg/kg.
Tissue sample collection
At either 6 or 24 h following saline or LPS injections,
mice were euthanized by carbon-dioxide asphyxiation.
To measure mRNA expression of target genes, brain re-
gions (amygdala, hippocampus, striatum) were grossly
Fig. 1 Kynurenine pathway of tryptophan metabolism. Tryptophan is metabolized to kynurenine by indoleamine 2,3-dioxygenase (IDO), IDO-like
enzyme, IDO2, and tryptophan 2,3-dioxygenase (TDO). Tryptophan can also be metabolized by tryptophan hydroxylase (TrpH) and L-aromatic
amino acid decarboxylase (L-AADC) to serotonin (5-HT) which is further broken down by monoamine oxidase (MAO) to 5-hydroxyindoleacetic acid
(5-HIAA). Kynurenine can be metabolized to kynurenic acid (KA) by one of four isoforms of kynurenine aminotransferase (KAT), of which KATI and
KATII are most relevant to mammals. The production of KA by KATs mainly occurs in astrocytes, cells which predominantly express glial fibrillary
acidic protein (GFAP). Alternately, kynurenine can be metabolized to 3-hydroxykynurenine (3-HK) by kynurenine 3-monooxygenase (KMO). 3-HK is
metabolized to 3-hydroxyanthranilic acid (3-HAA) by kynureninase (KYNU) and 3-HAA to quinolinic acid (QA) by 3-hydroxyanthranilic acid dioxygenase
(HAAO). This branch of the kynurenine pathway is compartmentalized in microglia, indicated by ionized calcium-binding adapter molecule 1 (Iba1) and
CD11b expression. The elevation in expression of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), tumor necrosis factor α (TNFα), and
interleukin-6 (IL-6), during inflammatory conditions activates glial cells. Further, IDO expression is up-regulated and flux through the neurotoxic
kynurenine metabolic branch increases. Underlined targets were assessed by real-time RT-PCR to determine changes in mRNA
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dissected (based on stereological coordinates in a mouse
brain atlas [38]). Subsequent analysis of brain region me-
tabolites was performed on microdissected brain regions
harvested from serial 1-mm coronal brain sections using
a brain matrix (Stoelting Co., Wood Dale, IL) (based on
stereological coordinates in a mouse brain atlas [38]).
Tissue was snap frozen in liquid nitrogen and stored at
−80 °C until analyzed. At 24 h following injections, prior
to perfusion, blood was also collected for separation of
plasma, which was stored at −80 °C.
RNA isolation and real-time RT-PCR
Brain tissues (hippocampus, amygdala, striatum) collected
at 6 and 24 h post treatment (saline, LPS) were analyzed to
determine relative steady-state mRNA expression using
real-time RT-PCR. Isolation of RNA was carried out ac-
cording manufacturer instructions using a PureLink® RNA
Mini Kit (Life Technologies, Grand Island, NY), and cDNA
was created using a high-capacity cDNA RT kit (Life Tech-
nologies) following manufacturer instructions. Real-time
RT-PCR was performed over 40 cycles using a CFX384™
Real-Time PCR Detection System (Bio-Rad, Hercules, CA)
and Taqman® Gene Expression Assays (Life Technologies):
Gapdh (GAPDH, Mm99999915_g1), Il1b (IL-1β, Mm013
36189_m1),Tnf (TNFα, Mm00443258_m1), Il6 (IL-6, Mm0
0446190_m1), Itgam (CD11b, Mm00434455_m1), Aif1
(Iba1, Mm00479862_g1), Gfap (GFAP, Mm01253033_m1),
Ido (IDO, Mm00492586_m1), Ido2 (IDO2, Mm0052420
6_m1), Tdo2 (TDO, Mm00451266_m1), Ccbl1 (KATI,
Mm01327703_m1), Aadat (KATII, Mm00496169_m1),
Kmo (KMO, Mm00505511_m1), Kynu (KYNU, Mm00
551012_m1), and Haao (HAAO, Mm00517945_m1). Data
are expressed as relative fold change (Target ΔmRNA) using
the 2−ΔΔCt calculation method and GAPDH as the house-
keeping gene as previously described [12].
Liquid chromatography/mass spectrometry
Microdissected brain regions (dorsal and ventral hippocam-
pus, central amygdala, nucleus accumbens) and plasma
were prepared for liquid chromatography/mass spectrom-
etry (LC/MS) and analyzed for kynurenine metabolites as
previously described [23]. Briefly, thawed plasma samples
were diluted five times with 0.2 % acetic acid and 1 mM in-
ternal standards, transferred to Amicon Ultra filters
(Millipore, Billerica, MA) and centrifuged at 13,500×g for
1 h at 4 °C. Frozen brain regions were diluted 30 times with
0.2 % acetic acid and 1 mM internal standards and then
homogenized at 4 °C using a Bead Ruptor 24 Homogenizer
(Omni International, Kennesaw, GA) with 1.4-mm zirco-
nium ceramic oxide beads (Omni International) and set-
tings of (pulse duration 45 s, pulse number 2, rest interval
15 s). The supernatant was filtered in a centrifuge as the
plasma. Following preparation, samples were analyzed on a
Q Exactive mass spectrometer (Thermo Fisher Scientific,
Waltham, MA) with on-line separation by a Dionex UltiM-
ate 3000 HPLC system (Thermo Fisher Scientific), and the
data collected was analyzed using Xcalibur 2.2 software
(Thermo Fisher Scientific) in the Mass Spectrometry Core
Facility at the University of Texas Health Science Center at
San Antonio. Metabolite ratios were calculated, as an in
vivo estimation of IDO activity, kynurenine metabolic
balance, and serotonin turnover, from raw data that are part
of a separate study (Parrott JM, Redus L, Morales J, Xiaoli
G, O’Connor JC: Neurotoxic kynurenine metabolism is in-
creased in the dorsal hippocampus and drives distinct
depressive behaviors during inflammation, Submitted).
These values were used to determine the following ratios:
kynurenine/tryptophan, 3-HK/KA, and 5-HIAA/5-HT.
3-Hydroxyanthranilic acid (3-HAA) and QA were not
reliably detected in brain region microdissected samples
due to limited sample size.
Statistical analysis
Data were analyzed using SigmaPlot 12.0 software (Systat
Software Inc., San Jose, CA) and are presented as group
means + standard error of the mean (SEM). Following a
single-pass Chauvenet’s test for outliers as previously
described [26], data analysis was conducted using either a
t test or a one-way analysis of variance (ANOVA). Signifi-
cant main effects identified by the ANOVA were further
analyzed with the Holm-Sidak method for pairwise multiple
comparisons post hoc test to identify between-group differ-
ences. Significant treatment effects (p < 0.05, compared to
saline) are denoted as such (*), and trends (p < 0.1–0.05)
are denoted as such (#) (#p < 0.1–0.05; *p < 0.05–0.01;
**p < 0.01–0.001; ***p < 0.001).
Results
Peripheral lipopolysaccharide induces time-dependent
central pro-inflammatory cytokine expression
Inflammation precipitates depressive-like behaviors that are
controlled by neurocircuits within distinct regions of the
brain, yet the impact of peripheral immune activation on
pro-inflammatory cytokine expression within these regions
has not been thoroughly characterized. To confirm the time
course and regional response of pro-inflammatory cytokine
expression following peripheral LPS challenge, interleukin-
1β (IL-1β), tumor necrosis factor α (TNFα), and
interleukin-6 (IL-6) were measured 6 and 24 h post treat-
ment. In the hippocampus, IL-1β expression (Fig. 2a, left
panel) was elevated relative to saline at both 6 h (p < 0.001)
and 24 h (p < 0.001) post LPS injections. Similarly, TNFα
expression (Fig. 2a, center panel) also increased from saline
following LPS injections at both 6 h (p < 0.001) and 24 h
(p < 0.001). IL-6 expression (Fig. 2a, right panel) was only
elevated at 6 h (p < 0.001) post LPS treatment and returned
to saline expression levels by 24 h. In the amygdala, both
IL-1β (Fig. 2b, left panel) and TNFα expression (Fig. 2b,
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center panel) followed a similar pattern of increased ex-
pression at 6 h (p < 0.001 IL-1β; p < 0.001 TNFα) and 24 h
(p < 0.001 IL-1β; p < 0.001 TNFα) following LPS injections.
As in the hippocampus, IL-6 expression (Fig. 2b, right
panel) in the amygdala was elevated at 6 h (p < 0.001)
post LPS treatment; however, expression was signifi-
cantly decreased relative to saline at 24 h (p = 0.018)
post-LPS. IL-1β (Fig. 2c, left panel) and TNFα expression
(Fig. 2c, center panel) in the striatum was elevated com-
pared to saline at both 6 h (p < 0.001 IL-1β; p < 0.001
TNFα) and 24 h (p < 0.001 IL-1β; p < 0.001 TNFα) post
LPS injections. IL-6 expression (Fig. 2c, right panel) in the
striatum only increased at 6 h (p < 0.001) following LPS
treatment and decreased relative to saline levels by 24 h (p
= 0.001) post injections. Together, these data demonstrate
that in the hippocampus, amygdala, and striatum, there is a
similar pro-inflammatory cytokine temporal response fol-
lowing a peripheral inflammatory stimulus, such as LPS.
Markers of glial activation increase in response to
peripheral LPS challenge
Previous studies have demonstrated regional heterogen-
eity in microglia cell distribution [39] and activation fol-
lowing peripheral LPS injections [40]. To determine the
temporal and regional expression of glial markers fol-
lowing peripheral LPS, mRNA expression of cluster of
differentiation molecule 11b (CD11b), ionized calcium-
binding adapter molecule 1 (Iba1), and glial fibrillary
acidic protein (GFAP) were measured. In the hippocam-
pus, CD11b expression (Fig. 3a, left panel), a cellular
marker of microglia, was significantly elevated at 24 h
(p < 0.001) post LPS treatment. Iba1 (Fig. 3a, center
panel), another marker of microglia activation, was lower
than saline at 6 h (p < 0.001) while expression was sig-
nificantly elevated at 24 h (p < 0.001) post LPS injections.
The astrocytic marker, GFAP (Fig. 3a, right panel), was
also up-regulated relative to saline at both 6 h (p < 0.001)
and 24 h (p < 0.001) following peripheral LPS treatment.
In the amygdala (Fig. 3b, left, center, right panels), the
expression pattern of glial markers was nearly identical to
that observed in the hippocampus, with the exception that
post hoc analysis revealed that CD11b expression was
not significantly different from saline at either 6 or 24 h
post LPS. In the striatum, CD11b expression (Fig. 3c,
left panel) decreased at 6 h (p = 0.021) and increased at
24 h (p = 0.043) following LPS injections. Iba1 expres-
sion (Fig. 3c, center panel) in the striatum decreased at
6 h (p < 0.001) and was elevated at 24 h (p < 0.001) post
LPS treatment. Finally, GFAP expression (Fig. 3c, right
panel) was up-regulated relative to saline expression at
both 6 h (p < 0.001) and 24 h (p < 0.001) after peripheral
LPS. Similar to pro-inflammatory cytokines, these data
suggest that glial activation is relatively uniform across
discrete brain regions with up-regulation of astrocytic
markers preceding microglial markers.
Peripheral LPS challenge increases central indoleamine
2,3-dioxygenase expression
Previous studies have established that pro-inflammatory
cytokines up-regulate the expression of IDO which is ne-
cessary for the development of inflammation-associated
depressive-like behaviors [19]. However, IDO2 and TDO
are also expressed in the brain and whether they contribute
to increased kynurenine metabolism after peripheral LPS
challenge is not known. Therefore, the expression of IDO,
TDO, and IDO2 (Fig. 1) was assessed. IDO expression
Fig. 2 Central pro-inflammatory cytokines are elevated following
peripheral LPS injections. mRNA fold changes (ΔmRNA) of
interleukin-1β (IL-1β, left panel), tumor necrosis factor α (TNFα,
middle panel), and interleukin-6 (IL-6, right panel) were measured at 6
and 24 h post LPS treatment in the (a) hippocampus, (b) amygdala,
and (c) striatum. Data represent sample means ± SEM, n = 8–11
samples/group. * = post hoc comparison to saline treatment group.
*p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
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(Fig. 4a–c) was elevated relative to saline at both 6 h
(p < 0.001 hippocampus, p < 0.001 amygdala, p < 0.001 stri-
atum) and 24 h (p < 0.001 hippocampus, p < 0.001 amyg-
dala, p < 0.001 striatum) post LPS treatment. In the
hippocampus (Fig. 4d, left panel) and amygdala (Fig. 4e, left
panel), IDO-like enzyme (IDO2) expression was decreased
from saline expression at 24 h (p < 0.001 hippocampus, p
= 0.042 amygdala) following LPS administration, while no
significant difference was observed in the striatum. There
was a trend for an overall effect of time for TDO expres-
sion (F2,24 = 3.12, p = 0.063) in the hippocampus (Fig. 4d,
right panel). In the amygdala, there was not a significant
change in TDO expression (Fig. 4e, right panel) following
LPS treatment. Similar to the hippocampus, striatal TDO
expression (Fig. 4e, right panel) tended toward an overall
effect of time (F2,27 = 2.95, p = 0.069). Together, these data
demonstrate that IDO is the only rate-limiting enzyme of
the kynurenine pathway that is significantly up-regulated
following peripheral immune challenge with LPS.
Kynurenine aminotransferases I and II are impacted in a
regionally dependent manner following peripheral
lipopolysaccharide
Under basal conditions, the majority of kynurenine is
metabolized to KA by kynurenine aminotransferases
(KAT) I and II (Fig. 1), the expression of which is not
thought to be impacted by inflammation [41]. The re-
gional and temporal mRNA expression pattern of KATI
and KATII was measured. In the hippocampus, KATI
expression (Fig. 5a, left panel) was significantly elevated
at 6 h (p = 0.005) and significantly decreased at 24 h
(p = 0.001) relative to saline following LPS treatment.
KATII expression in the hippocampus (Fig. 5a, right
panel) was significantly decreased at 24 h (p = 0.013)
following treatment with LPS. In the amygdala, both
KATI (Fig. 5b, left panel, F2,27 = 3.35, p = 0.050) and
KATII expression (Fig. 5b, right panel, F2,27 = 2.93, p =
0.071) trended toward significance for an overall effect
of time following LPS injections. In the striatum, there
was a significant overall effect of time for KATI ex-
pression (Fig. 5c, left panel, F2,26 = 5.32, p = 0.012)
after LPS treatment, though neither 6-h expression
nor 24-h expression was significantly different from
saline. Similarly, striatal KATII expression (Fig. 5b, right
panel, F2,24 = 7.78, p = 0.002) was significantly impacted by
LPS in which 6-h expression (p = 0.096) trended toward a
decrease while 24-h expression (p = 0.074) trended toward
an increase relative to saline expression. These data sug-
gest that peripheral LPS treatment does cause a modest
time- and region-dependent change in the expression of
KATI and KATII within the brain.
Peripheral LPS induces expression changes in neurotoxic
kynurenine pathway enzymes
Though it has been demonstrated that peripheral LPS in-
creases whole brain metabolism of kynurenine through
the neurotoxic branch [23], the regional or temporal ex-
pression pattern of the associated pathway enzymes has
not been reported. Kynurenine 3-monooxygenase (KMO),
kynureninase (KYNU), and 3-hydroxyanthranilic acid
dioxygenase (HAAO) (Fig. 1) mRNA was measured by
real-time RT-PCR. In the hippocampus, KMO expression
(Fig. 6a, left panel) was significantly elevated at 6 h
(p = 0.024) following LPS treatment. KYNU expression
(Fig. 6a, middle panel) was unchanged in response to per-
ipheral LPS. Hippocampal HAAO expression (Fig. 6a,
right panel) significantly decreased at 6 h post LPS treat-
ment (p < 0.001) and returned to saline expression levels
Fig. 3 Peripheral inflammation up-regulates central expression of
glial cell markers. mRNA fold changes (ΔmRNA) of CD11b (left panel),
ionized calcium-binding adapter molecule 1 (Iba1, middle panel), and
glial fibrillary acid protein (GFAP, right panel) were measured at 6 and
24 h post LPS treatment in the a hippocampus, b amygdala, and c
striatum. Data represent sample means ± SEM, n = 9–11 samples/
group. * = overall significance or post hoc comparison to saline
treatment group. *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
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by 24 h. The same expression pattern was measured in
the amygdala for each target. KMO mRNA was signifi-
cantly increased (Fig. 6b, left panel, p < 0.001), KYNU was
unchanged (Fig. 6b, middle panel), and HAAO expression
(Fig. 6b, right panel) was decreased at 6 h (p = 0.004) but
not 24 h following LPS treatment. Finally, in the striatum,
KMO expression (Fig. 6c, left panel) was significantly ele-
vated at 6 h (p = 0.015) and returned to saline expression
at 24 h post LPS. A significant overall effect of time on
striatal KYNU expression (Fig. 6c, middle panel) was ap-
parent following LPS (F2,25 = 3.44, p = 0.048); however,
post hoc testing revealed that 6-h expression (p = 0.087)
and 24-h expression (p = 0.074) only trended to decrease
from saline expression. HAAO expression (Fig. 6c, right
panel) also decreased at 6 h (p < 0.001) and returned to sa-
line levels 24 h following LPS treatment. Taken together,
these data indicate that peripheral immune challenge with
LPS causes a robust increase in the expression of KMO
mRNA with a concomitant time and region-dependent
down-regulation of KYNU and HAAO.
Peripheral LPS causes a neurotoxic shift in hippocampal
kynurenine metabolism
Multiple studies have described the impact of LPS on
central tryptophan metabolism [19, 23, 42, 43], but little
is known about region-dependent tryptophan metabol-
ism during peripheral inflammation. The kynurenine/
tryptophan ratio, 3-HK/KA ratio, and 5-HIAA/5-HT ra-
tio were determined in four brain regions 24 h post LPS
treatment. LPS induced a significant increase in the
kynurenine/tryptophan ratio in each brain region: dorsal
hippocampus (Fig. 7a, p < 0.001), ventral hippocampus
Fig. 4 Peripheral LPS specifically increases expression of kynurenine producing enzyme, indoleamine 2,3-dioxygenase (IDO). mRNA fold changes
(ΔmRNA) of IDO were assessed at 6 and 24 h following LPS injections in the (a) hippocampus, (b) amygdala, and (c) striatum. mRNA expression of
IDO2 (left panel) and tryptophan 2,3-dioygenase (TDO, right panel) were also measured at 6 and 24 h post LPS in the (d) hippocampus, (e) amygdala,
and (f) striatum. Data represent sample means ± SEM, n = 8–11 samples/group. #,* = overall significance or post hoc comparison to saline treatment
group. #p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
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(Fig. 7b, p < 0.001), central amygdala (Fig. 7c, p < 0.001),
and nucleus accumbens (Fig. 7d, p < 0.001). The balance
of downstream kynurenine metabolism was shifted to-
ward the neurotoxic branch in the hippocampus with
the 3-HK/KA ratio significantly increased (dorsal; Fig. 7e,
left panel, p = 0.054 and ventral; Fig. 7f, left panel, p =
0.032). The 3HK/KA ratio was not different 24 h post
LPS in central amygdala (Fig. 7g, left panel) or nucleus
accumbens (Fig. 7h, left panel). While serotonin levels
were unchanged (data not shown), 5-HT metabolism to
5-HIAA was increased 24 h post LPS in the dorsal
hippocampus (Fig. 7e, right panel, p < 0.001), ventral
hippocampus (Fig. 7f, right panel, p < 0.001), and central
amygdala (Fig. 7g, right panel, p = 0.071). While the nucleus
accumbens 5-HIAA/5-HT ratio was not significantly in-
creased (Fig. 7h, right panel). Together, these data demon-
strate that LPS causes a general brain region-independent
increase in tryptophan metabolism and serotonin turnover,
Fig. 5 Kynurenine aminotransferases expression following peripheral
LPS treatment. mRNA fold changes (ΔmRNA) of kynurenine
aminotransferase I (KAT I, left panel) and kynurenine aminotransferase
II (KAT II, right panel) were measured at 6 and 24 h post LPS in the
(a) hippocampus, (b) amygdala, and (c) striatum. Data represent sample
means ± SEM, n= 8–11 samples/group. #,* = overall significance or post
hoc comparison to saline treatment group. #p < 0.1–0.05; *p < 0.05–0.01;
**p < 0.01–0.001; ***p < 0.001
Fig. 6 Peripheral inflammation alters expression of downstream
kynurenine pathway enzymes. mRNA fold changes (ΔmRNA) of
kynurenine 3-monooxygenase (KMO, left panel), kynureninase (KYNU,
middle panel), and 3-hydroxyanthranilic acid dioxygenase (HAAO,
right panel) were measured at 6 and 24 h following LPS injections in
the (a) hippocampus, (b) amygdala, and (c) striatum. Data represent
sample means ± SEM, n = 9–11 samples/group. #,* = post hoc com-
parison to saline treatment group. #p < 0.1–0.05; *p < 0.05–0.01;
**p < 0.01–0.001; ***p < 0.001
Parrott et al. Journal of Neuroinflammation  (2016) 13:124 Page 8 of 15
Fig. 7 Kynurenine/tryptophan ratio and hippocampal neurotoxic kynurenine metabolite ratio are up-regulated in response to peripheral LPS. The
kynurenine/tryptophan ratio was measured at 24 h following LPS injections in the (a) dorsal hippocampus, (b) ventral hippocampus,
(c) central amygdala, and (d) nucleus accumbens. Metabolite ratios of 3-hydroxykynurenine/kynurenic acid (3-HK/KA, neurotoxic ratio,
left panel) and 5-hydroxyindoleacetic acid/serotonin (5-HIAA/5-HT, serotonin turnover, right panel) were measured 24 h post LPS in the
(e) dorsal hippocampus, (f) ventral hippocampus, (g) central amygdala, and (h) nucleus accumbens. Data represent sample means ± SEM,
n = 7–12 samples/group. #p < 0.1–0.05; *p < 0.05–0.01; **p < 0.01–0.001; ***p < 0.001
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but downstream neuroactive kynurenine metabolism oc-
curs in a region-dependent manner.
Lipopolysaccharide increases peripheral kynurenine
metabolism toward the neurotoxic route
Because peripheral circulation is a significant source of
kynurenine for the brain [37], plasma tryptophan metabol-
ism was measured (Table 1). LPS treatment significantly
increased the concentration of tryptophan (Table 1,
p = 0.006), kynurenine (Table 1, p < 0.001), and 3-HK
(Table 1, p < 0.001). The concentration of 3-HAA
(Table 1), QA (Table 1), and KA (Table 1) remained un-
changed 24 h after LPS treatment. The kynurenine/trypto-
phan ratio (Table 1, p < 0.001) and the 3-HK/KA ratio
(Table 1, p < 0.001) were also significantly increased
following LPS injections. These data indicate that LPS pre-
cipitates a robust up-regulation of kynurenine metabolism
that is shifted toward the neurotoxic branch; however,
neuroactive metabolic end products were not increased.
Discussion
Under the guidelines of the RDoC framework, a renewed
emphasis has been placed on understanding regionally
distinct structural, cellular, and molecular events in-
volved in the pathogenesis of neuropsychiatric disease
[29, 30]. Therefore, the objective of this study was to
characterize the LPS-induced neuroinflammatory re-
sponse in brain regions relevant to depression-related
symptoms as previous literature has described these data
only at the whole brain level. Up-regulation of pro-
inflammatory cytokine expression (IL-1β, TNFα, and IL-6)
followed the same temporal pattern in each of the three
regions studied (hippocampus, amygdala, and striatum)
following peripheral LPS challenge. The relative magni-
tude of the LPS-induced cytokine response was similar as
well. Likewise, glial cell markers (CD11b, Iba1, and GFAP),
in general, were elevated in a region-independent manner.
Interestingly, up-regulation of astrocytic marker GFAP
preceded the subsequent increase in microglial markers
CD11b and Iba1. Consistent with studies demonstrating
that IDO expression is induced by pro-inflammatory cyto-
kines, IDO expression was robustly up-regulated in a
region-independent manner, peaking at 6 h following LPS
treatment, while IDO2 and TDO remained largely un-
changed. Interestingly, the expression of neurotoxic
kynurenine pathway enzymes downstream of IDO (KMO,
KYNU, and HAAO) was also similar between brain re-
gions; however, each enzyme had a unique response pat-
tern following peripheral inflammation. KMO expression
increased, KYNU expression remained unaffected, and
HAAO expression decreased as an immediate response to
LPS treatment. On the opposing metabolic branch, KAT
enzymes (I and II) were significantly down-regulated in
the hippocampus, 24 h after LPS treatment. In accord
with the mRNA data, functional assessment of kynurenine
metabolism showed that the kynurenine/tryptophan ratio
increased approximately twofold following peripheral im-
mune activation in the same pattern throughout the regions
assessed. Interestingly, the 3-HK/KA ratio, which reflects
the relative neurotoxic/neuroprotective metabolic balance,
was only up-regulated in the hippocampal regions (dorsal
and ventral) following LPS treatment. Together, these data
demonstrate that peripheral immune challenge results in
region-independent induction of neuroinflammation and
kynurenine production, while downstream metabolism of
kynurenine is region specific.
To characterize the neuroinflammatory response associ-
ated with peripheral immune activation, pro-inflammatory
cytokine and glial cellular marker expressions were
assessed. The expression of all three pro-inflammatory
cytokines, IL-1β, TNFα, and IL-6 were increased 6 h after
LPS injections in all three brain regions, similar to pre-
viously published data from the hippocampus, cortex,
and hypothalamus [17, 44]. This early central pro-
inflammatory response drives the development of LPS-
induced sickness behavior (lethargy, decreased appetite,
Table 1 Peripheral inflammation increases flux through the kynurenine pathway of tryptophan metabolism
Metabolite Concentration (μM) t test
Saline 24 h LPS p value
Tryptophan 94.93 (7.1) 119.53 (3.9) p < 0.01
Kynurenine 0.83 (0.08) 2.40 (0.2) p < 0.001
3-Hydroxykynurenine (3-HK) 0.16 (0.02) 0.27 (0.04) p < 0.001
3-Hydroxyanthranilic acid (3-HAA) 3.99 (0.3) 4.87 (0.4) n.s.
Quinolinic acid (QA) 0.98 (0.06) 0.97 (0.07) n.s.
Kynurenic acid (KA) 0.24 (0.03) 0.27 (0.01) n.s.
Kynurenine/tryptophan ratio 0.0092 (0.0004) 0.020 (0.005) p < 0.001
3-HK/KA ratio 0.55 (0.04) 1.08 (0.07) p < 0.001
Kynurenine pathway metabolites (μM) were assessed by LC/MS in the plasma 24 h following saline or LPS treatment. Metabolites measured include tryptophan,
kynurenine, 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), quinolinic acid (QA), and kynurenic acid (KA). Kynurenine/tryptophan and 3-HK/KA
ratios were calculated. Data represent sample means (SEM) and were analyzed using a t test (results denoted in table). n = 7–12 samples/group, n.s. not significant
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reduced social interactions, fever) [45, 46]. At 24 h
post-LPS treatment, IL-1β and TNFα expression
remained elevated while IL-6 returned to saline expres-
sion levels, also an effect similar to previously pub-
lished results [17]. It is important to note that under
the experimental conditions of this study, 24 h after
LPS treatment corresponds to when depressive-like be-
haviors have been assessed previously [47]. It is possible
that the culmination of IL-6 prior to IL-1β and TNFα
expression is associated with the resolution of a specific
behavior, such as fever [48], while other behaviors per-
sist at 24 h post-LPS and IL-1β and TNFα play an im-
portant role in the development of those behaviors. It is
important to note that using steady-state mRNA ana-
lysis of brain neuroinflammatory targets has both merit
and limitations. In our study, mRNA targets allow for
an extremely sensitive and quantitative measure of
neuroinflammatory gene expression. Since many pro-
inflammatory cytokines, including IL-1β, TNFα, and IL-
6, are able to enter the brain via transport across the
blood brain barrier [49, 50], determination of mRNA
expression ensures that any changes being measured
reflect the local brain expression of the targets, not the
appearance/accumulation of peripherally secreted cyto-
kines. However, it is possible that variability in transla-
tion dynamics of mRNA to protein could influence the
expression of de novo synthesized neuroinflammatory
targets.
Interestingly, the early up-regulation of central pro-
inflammatory cytokine mRNA was coupled with a gen-
eral down-regulation of microglial markers (CD11b and
Iba1) and increase of astrocytic GFAP. At both time
points after LPS, expression of astrocyte cell marker
GFAP was up-regulated, which is consistent with a
previous study demonstrating that central LPS adminis-
tration increases GFAP expression [51]. Microglia are
known to be the predominant cellular producers of pro-
inflammatory cytokines in the brain, and Iba1 expression
and/or staining are often reported as a proxy of activa-
tion state [52]. The incongruence in the expression pat-
terns between the gene targets in our study suggests that
expression of pro-inflammatory cytokines precede the
up-regulation of microglia-specific markers. Additionally,
utilization of CD11b or Iba1, in the absence of morphologic
or other complementary data, appears to be an insufficient
representation of microglia activation state. Moreover, the
temporal difference between up-regulation of astrocyte ver-
sus microglial markers suggests the possibility of a dynamic
role for these two cell types in mediating the neuroinflam-
matory response. This could be particularly relevant in
terms of kynurenine metabolism which is a pathway com-
partmentalized between astrocytes and microglia in the
brain [24, 53]. It is interesting to note that both CD11b and
GFAP are increased in their respective cell populations by
increases in nitric oxide (NO) production [54, 55], which
can be generated by elevations in pro-inflammatory cyto-
kines and kynurenine metabolite QA [56–58]. Further in-
vestigation is warranted to more precisely explore this
phenomenon.
The expression of all known rate-limiting kynurenine
producing enzymes, IDO, IDO2, and TDO, was assessed
to better understand how tryptophan is metabolized
following peripheral LPS. IDO expression was increased
at both 6 and 24 h post LPS injections in each brain re-
gion assessed, consistent with two previously published
studies [17, 44]. IDO2 is a more recently discovered
homologue of IDO with much lower enzymatic activity
compared to IDO [59]. In the hippocampus and amyg-
dala, IDO2 expression decreased at 24 h following LPS
while otherwise remaining unchanged, which follows
conflicting previous studies demonstrating that pro-
inflammatory stimuli increased or had no impact on
IDO2 mRNA [60, 61]. Overall, TDO expression did not
increase in any brain region at either time point in re-
sponse to LPS treatment, confirming previous reports
demonstrating that TDO expression is up-regulated by
glucocorticoids [62]. Together, these data confirm that
IDO is the only rate-limiting kynurenine pathway en-
zyme up-regulated in response to peripheral LPS, dem-
onstrating increased capacity for de novo kynurenine
production during neuroinflammatory conditions.
The metabolism of kynurenine is physically compart-
mentalized within the brain [24, 53]. Astrocytes express
mainly KATs (not KMO) for conversion of kynurenine
to KA [63, 64]. Microglia express KMO (not KATs) that
metabolizes kynurenine along the neurotoxic branch,
leading to the potential formation of several neurotoxic
metabolites [65, 66]. Contemporary research suggests
that the relative balance of these opposing metabolic
branches, rather than simply changes in the levels of in-
dividual metabolites, constitutes the pathogenic potential
of kynurenine metabolism [53]. Though LPS treatment
increased GFAP expression and presumably astrocytic
activation, there was only a significant increase in KATI
expression in the hippocampus at 6 h post injections.
Further, at 24 h post-LPS, KATI and KATII expression
was reduced in the hippocampus. A previous expression
study reported that LPS treatment did not affect KATII
expression in the hippocampus and cortex [44], in con-
trast with our results in the hippocampus. The data re-
ported here, suggesting that KAT expression (I and II) is
generally unchanged by LPS treatment, are consistent
with previous findings that demonstrate that whole brain
KA concentration levels do not increase at 24 h post-
LPS treatment [23]. Instead, that same study demon-
strated that peripheral LPS-induced elevations in central
kynurenine result in increases in 3-HK, 3-HAA, and QA
on the neurotoxic branch, mediated through KMO in
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microglia [23]. Interestingly, KMO was the only neuro-
toxic enzyme up-regulated following LPS treatment,
while KYNU expression did not change and HAAO de-
creased expression following LPS treatment. In a previ-
ous study, at 4 h post-LPS, KMO expression decreased
in the cortex, and at 24 h post-LPS, expression increased
in both the cortex and hippocampus [44]. The experi-
mental conditions, such as species (rats) and LPS dose
(0.25 mg/kg), are likely contributors to the differences in
expression kinetics between the two studies. In our
study, it is noteworthy to consider the possibility that
HAAO expression is down-regulated as a compensatory
response to the increased expression of KMO and the
potential increase in flux of metabolites through the
neurotoxic branch. Interestingly, the disconnect between
expression of microglia cell markers (Iba1, CD11b) and
KMO provides further evidence that the functional cel-
lular response is not necessarily accurately reflected by
measuring standard microglial markers.
To further explore the effects of LPS on kynurenine
metabolic balance within behaviorally relevant brain
regions, we calculated ratios that (1) reflected IDO activ-
ity and up-regulation of overall kynurenine metabolism
(kynurenine/tryptophan), (2) indicated the relative bal-
ance of kynurenine metabolism toward the neurotoxic
branch (3-HK/KA), and (3) assessed serotonin turnover
(5-HIAA/5-HT). Twenty-four hours post LPS was chosen
as the sampling time point based on established behavioral
kinetics [47]. Additionally, mRNA increases measured at
6 h post-LPS require time in order for protein translation
to begin impacting metabolism relevant to behavior
changes. In all of the regions assessed, the kynurenine/
tryptophan ratio was elevated as predicted based on IDO
expression data and previously published data [18, 19, 23,
67]. However, assessment of the 3-HK/KA ratio, indicative
of metabolism down the neurotoxic kynurenine branch,
revealed that peripheral LPS treatment only increased this
neurotoxic ratio in the dorsal and ventral hippocampus.
Relevant to this, a recent study suggested that microglia in
separate regions of the brain have functionally distinct
characteristics, specifically that those in the hippocampus
are more pro-inflammatory in nature [68]. As the main
producers of neurotoxic kynurenine metabolites, these
more immunovigilant hippocampal microglia might drive
the region-specific shift toward neurotoxic metabolism
observed here. Alternatively, it is possible that astrocytic
production of KA may follow a region-dependent pattern,
although this has yet to be directly investigated. Further,
while not significant, increasing statistical power may
actually reveal that the 3-HK/KA ratio decreases in the
nucleus accumbens in response to peripheral LPS treat-
ment. This will require additional future experiments.
Interestingly, recent data collected from a chronic social
defeat model, also associated with a peripheral immune
response, demonstrated regional variation in the up-
regulation of central kynurenine and 3-HK production
[69]. However, when brain region kynurenine metabolites
were assessed in response to peripheral CD40 antibody
treatment, which induces inflammation, both kynurenine
and 3-HK were elevated in all of the regions assessed [70].
Previous studies have demonstrated that peripheral LPS
treatment increases serotonin turnover in the whole brain
[19]. In line with those data, the 5-HIAA/5-HT ratio was
increased or trended to increase in all the regions assessed
in this study, except the nucleus accumbens. Together,
these data illustrate, for the first time, that brain kynure-
nine metabolism is regulated in a regionally distinct man-
ner following peripheral immune challenge with LPS. Our
recently published data support the notion that this neuro-
toxic shift is functionally relevant, as targeted deletion of
the KMO gene protects mice from LPS-induced disruption
in a hippocampal-dependent behavioral task [26].
As a control measure, tryptophan and kynurenine me-
tabolites were assessed in the plasma 24 h after LPS
treatment (Table 1). As predicted, LPS increased kynure-
nine, 3-HK, the kynurenine/tryptophan ratio, and the 3-
HK/KA ratio and did not change KA. Curiously, the
tryptophan concentration increased as well, contrary to
previous clinical and preclinical studies demonstrating
that inflammation is associated with a decrease in tryp-
tophan or ‘tryptophan depletion’ [16, 19, 71]. Further,
there were no changes in 3-HAA or QA after LPS treat-
ment, again differing from previous studies showing LPS
elevates peripheral and central QA as well as central 3-
HAA [23, 71]. The current study is the first to explore
kynurenine metabolic balance downstream of IDO in
C57BL/6J inbred mice while previous studies were
carried out in CD-1 outbred mice [23]. The dissociation
between central and peripheral downstream kynurenine
metabolites has also been observed in the clinic, when
cerebrospinal fluid QA was elevated without an increase in
plasma QA in hepatitis C patients receiving interferon-α
immunotherapy [72]. Importantly, our data revealed that
even though kynurenine/tryptophan doubles in both the
peripheral circulation and in each of the brain regions
measured (supporting the notion of the periphery as a pri-
mary source of these amino acids), the manner in which
kynurenine metabolism proceeds is not simply a function
of substrate levels. The distinct 3-HK/KA ratios, in the face
of uniform increases in kynurenine/tryptophan ratios, fur-
ther underscore that downstream brain region metabolism
is regionally discrete and locally regulated. Understanding
how local metabolic changes impact the behaviors medi-
ated by distinct brain regions remains an important area
for future study. Together, these data demonstrate that per-
ipheral LPS up-regulates the metabolism of tryptophan
and kynurenine to 3-HK, in both the periphery and the
brain. However, region-dependent regulation of kynurenine
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metabolic balance within the brain is potentially pertinent
to the pathogenesis of depression and is a therapeutically
relevant finding.
Conclusions
The main goal of this study was to provide a better
understanding of the regional neuroinflammatory re-
sponse following peripheral treatment with LPS. This
response involved mRNA expression (Fig. 1) of pro-
inflammatory cytokines (IL-1β, TNFα, IL-6), glia cell
markers (CD11b, Iba1, GFAP), and kynurenine path-
way enzymes (IDO, IDO2, TDO, KATI, KATII, KMO,
KYNU, HAAO) at 6 and 24 h post LPS in relevant
brain regions (hippocampus, amygdala, striatum).
Additionally, kynurenine metabolite ratios (kynure-
nine/tryptophan, 3-HK/KA, 5-HIAA/5-HT) were cal-
culated from previously collected data at 24 h post-LPS
in relevant brain regions (dorsal and ventral hippocampus,
central amygdala, nucleus accumbens). In general, these
data demonstrated that in response to peripheral LPS
treatment, pro-inflammatory cytokines and glia cell
makers increase similarly throughout the brain. Kynure-
nine pathway enzymes have distinct temporal expression
changes following LPS, which are region-independent;
however, the metabolic balance is regulated in a region-
dependent manner. Further analysis of the individual me-
tabolite concentrations and additional brain regions will
advance the understanding and potential implications of
brain region-specific kynurenine metabolism. The possi-
bility that individual depression-related behaviors are
driven by regionally defined disruptions in kynurenine
metabolism provides a specific target for future pharma-
cotherapy developments.
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